MENS vs MLTX

Jyong Biotech Ltd. vs MoonLake Immunotherapeutics — Valuation Comparison 2026

MENS

Pharmaceutical Preparations
Jyong Biotech Ltd.
Quality
2.3
out of 10
Value Trap
Price
$2.20
Last close
Models
9/13
Active
VS

MLTX

Pharmaceutical Preparations
MoonLake Immunotherapeutics
Quality
4.0
out of 10
Value Trap
30
LOW
Price
$19.18
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType MENS Fair ValueMENS Upside MLTX Fair ValueMLTX Upside
Bayesian DCF Intrinsic $0.56 -74.7% $6.26 -67.4%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Markov DDM Intrinsic $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $1.59 -27.5% $0.45 -97.3%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
RCMH-DCF Intrinsic $0.17 -92.1%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for MENS vs MLTX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MENS vs MLTX — Which Stock Is More Undervalued?

MLTX scores higher with a 4.0/10 quality rating vs MENS's 2.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Jyong Biotech Ltd. (MENS) and MoonLake Immunotherapeutics (MLTX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MENS currently trades at $2.20 with a QOC of 2.3/10, while MLTX trades at $19.18 with a QOC of 4.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).